Who Paid My Doc
Vishal Mehra
Cardiovascular Disease Danville, PA
NPI 1306934740 CMS profile 911821
100 N Academy Ave, Danville, PA 17822
General payments
$0
Research payments
$0
Ownership & investment interest
$0
The CMS Open Payments record contains no reported payments to Vishal Mehra of Danville, PA.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
Prescribing to Medicare patients
Part D · data year 2024 · 22 drugsPart D claims
1,123
Drug cost
$1,531,547
Branded share of claims
34%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Camzyos Mavacamten | Brand | 140 | $1,116,446 | |
| Vyndamax Tafamidis | Brand | 12 | $271,418 | |
| Repatha Sureclick Evolocumab | Brand | 91 | $57,869 | |
| Eliquis Apixaban | Brand | 35 | $38,078 | |
| Entresto Sacubitril/Valsartan | Brand | 26 | $24,683 | |
| Repatha Pushtronex Evolocumab | Brand | 16 | $10,942 | |
| Metoprolol Succinate | Generic | 142 | $2,656 | |
| Rosuvastatin Calcium | Generic | 66 | $1,432 | |
| Ezetimibe | Generic | 55 | $1,201 | |
| Losartan Potassium | Generic | 41 | $1,058 |
The 10 drugs with the highest cost, of 22 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 37 billing codesPaid by Medicare
$36,483
Medicare patients
1,818
Services billed
2,753
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 44% | |
| Arthritis | 44% | |
| Chronic kidney disease | 40% | |
| Diabetes | 39% | |
| Heart failure | 39% | |
| Atrial fibrillation | 39% | |
| Depression | 30% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Other Cardiovascular Disease in Pennsylvania
Hemal Gada
Cardiovascular Disease · Wormleysburg, PA
Benjamin Kalsmith
Cardiovascular Disease · Pgh, PA
Peter Kowey
Cardiovascular Disease · Wynnewood, PA
Paul Forfia
Cardiovascular Disease · Philadelphia, PA
Quang Bui
Cardiovascular Disease · Philadelphia, PA
Rhian Davies
Cardiovascular Disease · York, PA
Related records
Cardiovascular Disease in Pennsylvania
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Pennsylvania
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.